Valuation dashboard for None (BLRX) with P/E N/A, P/B N/A, EV/EBITDA N/A and dividend yield N/A. DCF, Graham Number and Earnings Power Value models plus sector comparison against other peers companies.
BioLineRx Ltd., an Israeli biopharmaceutical firm established in 2003 and based in Hevel Modi'in, focuses its clinical-stage development efforts primarily on oncology. Their leading investigational product, Motixafortide, a peptide, has successfully concluded pivotal Phase 3 clinical trials for mobilizing stem cells in autologous transplants, and Phase 2a trials targeting pancreatic cancer.
Analysis Summary
Balance sheet quality for BLRX: current ratio of 2.0. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Models
| DCF Fair Value | $0.24 |
| vs Current Price | -90.2% |
Price
| Price | $2.48 |
| Market Cap | $11M |
Related companies: ADAP · ADTX · AIMD · ANL · APLM · GOVX · ICU
More sections of BLRX: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks